

12TH INTERNATIONAL

# CLINICAL CANCER GENOMICS CONFERENCE

THURSDAY, APRIL 18, 2024 | PRE-CONFERENCE  
PRECISION MEDICINE IN PRACTICE PRIMER AND CASE-BASED WORKSHOP

APRIL 19-21, 2024 | FAIRMONT CHICAGO MILLENNIUM PARK, CHICAGO, IL

**ACCELERATING PROGRESS  
IN PRECISION MEDICINE  
FOR CANCER:**


THE TIME IS NOW



AT THE FOREFRONT  
**UChicago  
Medicine**

CLINICAL CANCER GENOMICS  
COMMUNITY OF PRACTICE



 City of Hope

THIS ACTIVITY IS BROUGHT TO YOU IN PARTNERSHIP WITH CITY OF HOPE

# INFORMATION

## COURSE DESCRIPTION

Rapid advances in genomic technologies have revolutionized our approach to risk-adapted cancer treatments and screening for early detection or prevention of cancer, heralding the era of precision health care across the continuum of cancer care. Knowledge of the genomic landscape and immune microenvironment of common cancers has fueled the need to identify cancer patients and healthy individuals at risk of the most lethal but treatable types of cancers where more intensive surveillance and personalized management plan can be implemented to improve overall survival. A classic example is identifying BRCA1 gene mutation carriers to preempt or prevent the development of lethal basal-like breast cancers and treating BRCA-Associated cancer with Parp Inhibitors. Identifying Lynch Syndrome patients led to the development of curative neoadjuvant immunotherapy approaches for Rectal Cancer.

**Accelerating Progress in Precision Medicine for Cancer: The Time is Now** will provide an interdisciplinary educational forum in which to update state-of-the-art science in cancer genomics, including Artificial Intelligence, discuss real-world cases, curate interesting pedigrees, and prepare case summaries to disseminate new knowledge and evidence-based management of high-risk patients and their at-risk family members. The goal of this educational activity is to equip healthcare providers with practical tools and knowledge to accelerate progress in precision medicine for cancer.

## TARGET AUDIENCE

This interdisciplinary and inter-professional educational activity has been designed for health care providers including advanced nurse practitioners, genetic counselors, oncology nurses, pharmacists, physicians, physician assistants, and other healthcare professionals involved in providing cancer genomics risk assessment services or initiating such services in their health care system. Special efforts will be made to meet the needs of clinicians practicing in non-academic centers and geographically and/or socioeconomically underserved communities.

## LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

- Review advances in genetics, genomics, and “Omics” technologies transforming precision medicine for cancer;

- Gain a better understanding of controversies in germline genomic testing for risk-adapted screening and integration of polygenic risk score for cancer prevention;
- Recognize advances in clinical research with special emphasis on patient-centric and biomarker informed clinical trials in high risk populations;
- Identify molecular determinants of response to therapy in hematologic malignancies and solid tumors;
- Appreciate patient advocacy and partnerships to accelerate progress in development of novel therapies and vaccines for cancer control;
- Learn how Artificial Intelligence is transform health care to promote health equity in the US and across the world.

## CONFERENCE LOCATION

Fairmont Chicago Millennium Park  
200 N. Columbus Drive  
Chicago, IL 60611  
United States

## ACCREDITATION AND CREDIT DESIGNATION

### PHYSICIAN CREDIT

The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 21.50 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

# INFORMATION

## ACCREDITATION AND CREDIT DESIGNATION CONTINUED

### GENETIC COUNSELOR CREDIT

The National Society of Genetic Counselors (NSGC) has authorized the University of Chicago Pritzker School of Medicine to offer up to 2.150 CEUs or 21.50 Category 1 contact hours for the activity 12th International Clinical Cancer Genomics Conference – Accelerating Progress in Precision Medicine for Cancer: The Time is Now! The American Board of Genetic Counseling (ABGC) will accept CEUs earned at this program for the purposes of genetic counselor certification and recertification.

### AMERICAN BOARD OF INTERNAL MEDICINE MOC PART II CREDIT

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 21.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

### NURSING CREDIT

University of Chicago Medicine is accredited as a provider of continuing nursing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Participants who successfully complete the entire activity and complete an evaluation form will earn 21.50 contact hours.

### OTHER HEALTHCARE PROFESSIONS CREDIT

Other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by the ACCME, please consult your professional licensing board.

### CME CERTIFICATES/ COURSE EVALUATION

The evaluation will be done when the participant comes to claim credit. Go to [www.cancergeneticsconference.com/](http://www.cancergeneticsconference.com/) to get information on how to claim CME.

### PLANNED BY



## EDUCATIONAL GRANTS/ COMMERCIAL SUPPORT

EDUCATIONAL GRANT FUNDING HAS BEEN GENEROUSLY PROVIDED BY:

### WE THANK OUR DIAMOND SPONSOR

- Astra Zeneca Oncology

### WE THANK OUR EXHIBITORS

#### PRODUCT THEATER LUNCHEON:

- CancerIQ

#### GOLD EXHIBITORS:

- Exact Sciences
- Invitae
- Pfizer

#### SILVER EXHIBITORS:

- Abbvie/ImmunoGen
- Astra Zeneca
- Blue Print Medicines
- Daiichi Sankyo
- Foundation Medicine
- Merck
- Regeneron

#### BRONZE EXHIBITORS:

- Grail Bio
- JNJ
- Menarini Stemline
- Myriad
- Natera
- Novartis
- Pfizer
- Recordati Rare Diseases, INC
- Takeda
- Tempus

#### NON PROFIT EXHIBITORS:

- Clinical Cancer Genomics Community of Practice/ City of Hope
- My Faulty Gene
- National Consortium of Breast Centers
- WISDOM/CAPS



# FACULTY

## CONFERENCE CO-DIRECTORS



### **Olufunmilayo Olopade, MD, FACP**

Walter L. Palmer Distinguished Service Professor  
Director, Center for Clinical Cancer Genetics  
Departments of Medicine and Human Genetics  
University of Chicago Medicine



### **Kathleen Blazer, EdD, MS, CGC**

Assistant Professor, Departments of  
Population Sciences and Medical Oncology  
Director, Cancer Genomics Education Program  
Director and Principle Investigator, Intensive  
Course and Clinical Cancer Genomics  
Community of Practice  
City of Hope National Medical Center

## SCIENTIFIC PROGRAM COMMITTEE

### **Kathleen Blazer, EdD, MS, CGC**

Assistant Professor, Departments of  
Population Sciences and Medical Oncology  
Director, Cancer Genomics Education Program  
Director and Principle Investigator, Intensive  
Course and Clinical Cancer Genomics  
Community of Practice  
City of Hope National Medical Center

### **Lorraine Canham, MD**

Instructor of Pediatrics  
Pediatric Hematology and Oncology  
University of Chicago Medicine

### **Jane Churpek, MD, MS**

Associate Professor  
Division of Hematology, Medical Oncology  
and Palliative Care  
Department of Medicine  
The University of Wisconsin School of Medicine  
and Public Health & The University of Wisconsin  
Carbone Cancer Center

### **Michael Drazer, MD, PhD**

Assistant Professor  
Hematology/Oncology  
University of Chicago Medicine

### **Christine Drogan MS, CGC**

Associate Director of the Gastrointestinal  
Cancer Risk and Prevention Clinic  
University of Chicago Medicine

### **William Foulkes, MBBS, PhD**

Senior Scientist, RI-MUHC  
Cancer Research Program  
Centre for Translational Biology  
Professor, Department of Medicine,  
Faculty of Medicine and Health Sciences  
McGill University

### **Rodrigo Santa Cruz Guindalini, MD, PhD**

Medical Oncologist  
Oncologia D'Or  
Rio de Janeiro, Brazil

### **Ashanti Hall-Williams**

Practice Manager  
General Surgery, Colorectal Surgery,  
and Breast Center  
University of Chicago Medicine

### **Sonia Kupfer, MD**

Associate Professor of Pathology  
Committee on Cancer Biology  
Committee on Immunology  
University of Chicago Medicine

### **Jan-Marie McEville, RN**

Head and Neck Nurse  
Biological Sciences Division of Medicine,  
Hematology, and Oncology  
University of Chicago Medicine

### **Olufunmilayo Olopade, MD, FACP**

Walter L. Palmer Distinguished Service Professor  
Director, Center for Clinical Cancer Genetics  
Departments of Medicine and Human Genetics  
University of Chicago Medicine

### **Tuya Pal, MD**

Associate Professor  
Department of Medicine (Genetic Medicine)  
Vanderbilt-Ingram Cancer Center  
Associate Director, Cancer Health Disparities  
Vanderbilt-Ingram Cancer Center

### **Colin Pritchard, MD, PhD**

Precision Diagnostics Platform Head  
Brotman Baty Institute for Precision Medicine  
University of Washington Medicine

### **Peter Savage, PhD**

Associate Professor of Pathology  
Committee on Cancer Biology  
Committee on Immunology  
University of Chicago Medicine

### **Russell Szmulewitz, MD**

Associate Professor of Medicine  
Director, Genitourinary Oncology Program  
Associate Director for Clinical Investigation  
Comprehensive Cancer Center  
University of Chicago Medicine

## INTERNATIONAL FACULTY

### **Aysel Ahadova, PhD**

Postdoctoral Fellow  
Department of Applied Tumor Biology  
University Hospital Heidelberg, Germany

### **William Foulkes, MBBS, PhD**

James McGill Professor, Departments of  
Medicine, Oncology and Human Genetics  
Director, Program in Cancer Genetics  
McGill University  
Montreal, Quebec, Canada

### **Rodrigo Santa Cruz Guindalini, MD, PhD**

Medical Oncologist  
Oncologia D'Or  
Rio de Janeiro, Brazil

### **Matthias Kloor, MD**

Physician Scientist  
University Hospital Heidelberg, Germany

### **Kelly Metcalfe, RN, PhD**

Senior Scientist  
Women's College Research Institute  
Professor and Associate Dean of Research  
Lawrence S. Bloomberg Faculty of Nursing  
and Faculty of Medicine  
University of Toronto, Canada

### **Steven Narod, MD, FRCPC, FRSC**

Senior Scientist  
Women's College Research Institute  
Director, Familial Breast Cancer Research Unit  
Professor, Dalla Lana School of Public Health  
and Department of Medicine  
University of Toronto, Canada

### **Raja Pramanik, MBBS, MD, DM, BA**

Associate Professor  
Department of Medical Oncology  
All India Institute of Medical Sciences

CONTINUED...

# FACULTY

## UNIVERSITY OF CHICAGO MEDICINE FACULTY

---

**Daniel Arber, MD**

Chair of Pathology  
Donald West and Mary Elizabeth King  
Professor of Pathology  
University of Chicago Medicine

**Lorraine Canham, MD**

Instructor of Pediatrics  
Pediatric Hematology and Oncology  
University of Chicago Medicine

**Michael Drazer, MD, PhD**

Assistant Professor  
Hematology/Oncology  
University of Chicago Medicine

**Christine Drogan MS, CGC**

Associate Director of the Gastrointestinal  
Cancer Risk and Prevention Clinic  
University of Chicago Medicine

**Cara Essling, MMSPA**

Physician Assistant  
Hematology and Oncology Cancer  
University of Chicago Medicine

**Gini Fleming, MD**

Professor of Medicine  
Director of Gynecologic Oncology  
University of Chicago Medicine

**Ophir Gilad, MD**

Research Fellow  
Department of Gastroenterology  
University of Chicago Medicine

**Feighanne Hathaway, MS, CGC**

Certified Genetic Counselor  
Center for Clinical Cancer Genetics  
& Global Health  
University of Chicago Medical Center

**Frederick Howard, MD**

Assistant Professor of Medicine  
Hematology and Oncology  
University of Chicago Medicine

**Dengzeng Huo, PhD**

Professor of Public Health Sciences  
Professor of Medicine  
University of Chicago Medicine

**Nora Jaskowiak, MD**

Professor of Surgery  
Surgical Director of the Breast Center  
University of Chicago Medicine

**Emma Keel, MS, CGC**

Certified Genetic Counselor  
Section of Gastroenterology  
University of Chicago Medicine

**Sonia Kupfer, MD**

Professor of Medicine  
Co-director, Comprehensive Cancer Risk  
and Prevention Clinic Director  
University of Chicago Medicine

**Kathryn Mills, MD**

Assistant Professor of Gynecological Oncology  
University of Chicago Medicine

**John Moroney, MD**

Associate Professor of Obstetrics  
and Gynecology  
Associate Professor of Medicine  
University of Chicago Medicine

**Rita Nanda, MD**

Associate Professor of Medicine  
Director of Breast Oncology Program  
University of Chicago Medicine

**Peter H. O'Donnell, MD**

Associate Professor Hematology/Oncology  
University of Chicago Medicine

**Melody Perpich, MS, CGC**

Certified Genetic Counselor  
Pediatric Oncology Hematology  
University of Chicago Medicine

**Iris Romero, MD, MS**

Professor of Obstetrics and Gynecology  
Dean for Diversity and Inclusion  
Executive Vice Dean of the Biological Sciences  
Division and the Pritzker School of Medicine  
University of Chicago Medicine

**Ari Rosenberg, MD**

Assistant Professor of Medicine  
Hematology and Oncology  
University of Chicago Medicine

**Loren Salsberry, PhD**

Assistant Program Leader of the Cancer  
Prevention and Control Program,  
University of Chicago Medicine  
Comprehensive Cancer Center

**Caner Saygin, MD**

Assistant Professor of Medicine  
Hematology and Oncology  
University of Chicago Medicine

**Jeremy Segal, MD, PhD**

Professor of Pathology  
Director, Molecular and Cytogenetic Pathology  
University of Chicago Medicine

**Wendy Stock MD**

Anjali Seth Nayak Professor of Medicine  
University of Chicago Medicine

**Rajat Thawani, MBBS**

Assistant Professor of Medicine  
Hematology and Oncology  
University of Chicago Medicine

## GUEST FACULTY

---

**Michelle Bruszer**

Patient Advocate

**Jane Churpek, MD, MS**

Associate Professor  
Division of Hematology, Medical Oncology  
and Palliative Care  
Department of Medicine  
The University of Wisconsin School of Medicine  
and Public Health & The University of Wisconsin  
Carbone Cancer Center

**Fergus Couch, PhD**

Professor of Laboratory Medicine and Pathology  
Chair, Division of Experimental Pathology  
and Laboratory Medicine, Department of  
Laboratory Medicine and Pathology  
Mayo Clinic

**Susan Domchek, MD**

Basser Professor in Oncology  
Executive Director, Basser Center for BRCA  
Director, MacDonald Women's Cancer  
Risk Evaluation Center  
Penn Medicine

**Sandra Dreike, MS, CGC**

Senior Genetic Counselor  
Division of Clinical Cancer Genomics  
Department of Medical Oncology and  
Therapeutics Research  
City of Hope

**Cathy Eng, MD**

David H. Johnson Chair in Surgical  
and Medical Oncology  
Co-Leader, Gastrointestinal Cancer  
Research Program  
Professor of Medicine (Hematology and Oncology)  
Co-Director, GI Oncology  
Vice-Chair, SWOG GI Committee  
Director, Vanderbilt-Ingram Cancer Center  
Young Adult Cancers Initiative  
Vanderbilt-Ingram Cancer Center

**Grace-Ann Fasaye, ScM, CGC**

Senior Genetic Counselor  
National Cancer Institute

CONTINUED...

# FACULTY

## GUEST FACULTY (CONT.)

### **Pamela Ganschow, MD**

Associate Professor  
Department of Internal Medicine  
College of Medicine  
University of Illinois Cancer Center

### **Judy Garber, MD, MPH**

Susan F. Smith Chair  
Chief of the Division of Cancer Genetics  
and Prevention  
Dana-Farber Cancer Institute  
Professor of Medicine  
Harvard Medical School

### **Lucy Godley, MD, PhD**

Jeffrey and Marianne Silver Family  
Professor of Oncology  
Professor of Medicine (Hematology and Oncology)  
Northwestern Medicine  
Feinberg School of Medicine

### **Stacy Gray, MD, AM**

Professor Medical Oncology and  
Therapeutics Research, Population Sciences  
Deputy Director, Center for Precision Medicine  
Division Chief, Clinical Cancer Genomics  
City of Hope

### **Stephen Gruber, MD, PhD, MPH**

Eva and Ming Hsieh Family Director's Chair  
of the Center for Precision Medicine  
Professor, Division of Molecular Pharmacology  
Department of Medical Oncology &  
Therapeutics Research  
Vice President  
City of Hope National Medical Center  
City of Hope

### **Joanne Jeter, MD**

Clinical Professor, Department of Medical  
Oncology & Therapeutics Research  
City of Hope

### **Wenora Johnson**

Patient/ Research Advocate

### **Peter Kuhn, PhD**

University Professor  
Dean's Professor of Biological Sciences  
Professor of Biological Sciences, Medicine,  
Biomedical Engineering, Aerospace and  
Mechanical Engineering and Urology  
Keck School of Medicine  
University of Southern California

### **Lisa Madlensky, PhD, CGC**

Professor of Medicine  
Genetic Counselor  
UC San Diego Health

### **Rachelle Manookian, MS, CGC**

Genetic Counselor  
Division of Clinical Cancer Genomics  
Department of Medical Oncology &  
Therapeutics Research  
University of Southern California

### **Kara Maxwell, MD, PhD**

Assistant Professor of Medicine  
Hematology Oncology  
Perelman School of Medicine  
University of Pennsylvania

### **Katherine Nathanson, MD**

Pearl Basser Professor for  
BRCA-Related Research  
Abramson Cancer Center  
University of Pennsylvania

### **Bitu Nehoray, MS, CGC**

Senior Genetic Counselor  
Division of Clinical Cancer Genomics  
Department of Medical Oncology &  
Therapeutics Research  
City of Hope

### **Afaf Osman, MD**

Assistant Professor  
University of Utah

### **Tuya Pal, MD**

Associate Director for Cancer Health Disparities  
Professor of Medicine  
Professor of Pediatrics  
Vanderbilt-Ingram Cancer Center

### **Helen Palmquist**

Patient Advocate

### **Colin Pritchard, MD, PhD**

Professor, Co-Director  
Genetics and Solid Tumors Laboratory  
Precision Diagnostics Platform Head  
Brotman Baty Institute For Precision Medicine  
University of Washington

### **Padma Sheila Rajagopal, MD, MPH, MSc, NCI**

Physician Scientist Early Investigator  
Cancer Data Science Laboratory  
National Cancer Institute

### **Katherine Roth, MD**

Postdoctoral Fellow  
Center for Precision Medicine  
City of Hope

### **Christina Rybak, MS, CGC**

Senior Genetic Counselor  
The City of Hope

### **Sharon Savage, MD**

Clinical Director  
Senior Investigator  
National Cancer Institute

### **Susan Shehayeb, MS, CGC**

Senior Genetic Counselor, Division of Clinical  
Cancer Genomics, Department of Medical  
Oncology & Therapeutics Research  
City of Hope

### **Yiwey Shieh, MD**

Assistant Professor of Population Health Sciences  
Assistant Professor of Medicine  
Weill Cornell Medical College  
Cornell University

### **Elise Sobotka, MS, MPH, CGC**

Genetic Counselor  
City of Hope

### **Ilana Solomon, MA, ScM, CGC**

Manager, Center for Precision Medicine  
City of Hope

### **Parul Somani, MBA**

Speaker and Patient Advocate

### **Mary Beth Terry, PhD**

Professor of Epidemiology  
Columbia University  
Mailman School of Public Health

### **David VanderWeele, MD, PhD**

Associate Professor of Medicine  
Hematology and Oncology  
Northwestern Medicine

### **Karriem Watson, DHSc, MS, MPH**

Chief Engagement Officer  
All of Us Research Program  
National Institutes of Health

### **Jeffrey Weitzel, MD**

Precision Prevention  
University of Kansas  
Comprehensive Cancer Center

### **Adam Yala, PhD**

Assistant Professor  
Computation Precision Health  
Department of Statistics  
University of California Berkeley

### **Elyssa Zukin, MS, CGC**

Genetic Counselor  
City of Hope

# AGENDA

## THURSDAY, APRIL 18, 2024

### PRE-CONFERENCE:

#### Precision Medicine in Practice Primer and Case-Based Workshop

ROUGE ROOM (1<sup>ST</sup> FLOOR)

- 1:00 pm **WELCOME**  
Kathleen Blazer, EdD, MS, CGC
- 1:10 pm **The Two Genomes of Cancer in Precision Medicine: Overview of the Tumor and Germline Genomes- Key Concepts and Terms in Precision Medicine**  
Padma Sheila Rajagopal, MD, MPH, MSc, NCI
- 1:30 pm **Technical Considerations in Tumor and Germline Testing: What Test Tells Us What**  
Colin Pritchard, MD, PhD
- 1:50 pm **Fundamental Concepts in Targeted Cancer Therapeutics**  
Katherine Roth, MD
- 2:10 pm **Germline Signatures Indicating Candidacy for Targeted Treatments and Clinical Trials and Somatic Signatures Indicating Candidacy for Germline Testing**  
Joanne Jeter, MD
- 2:40 pm **Q&A**
- 2:50 pm **BREAK**
- 3:10 pm **BREAKOUT SESSIONS**  
**ROUGE ROOM (1<sup>ST</sup> FLOOR)**  
**Putting It All Together: Team-Based Learning (TBL)**
- Moderators:** Kathleen Blazer, EdD, MS, CGC  
Sandra Dreike, MS, CGC  
Rachelle Manookian, MS, CGC  
Bita Nehoray, MS CGC  
Christina Rybak, MS, CGC  
Susan Shehayeb, MS, CGC  
Elise Sobotka, MS, MPH, CGC  
Ilana Solomon MA, ScM, CGC  
Elyssa Zukin, MS, CGC
- 3:50 pm **Team-Based Learning Case Presentations with Panel Discussion**
- Moderators:** Listed above
- Faculty Panel:** Joanne Jeter, MD, MS  
Colin Pritchard, MD, PhD  
Padma Sheila Rajagopal, MD, MPH, MSc, NCI  
Kathleen Roth, MD
- 5:00 pm **ADJOURN**

## FRIDAY, APRIL 19, 2024

7:00 am **REGISTRATION, BREAKFAST AND EXHIBITS**  
**INT'L. BALLROOM FOYER**

### SESSION 1: Survivorship in Patients at Risk for Multiple Cancers

**INTERNATIONAL BALLROOM**

- Moderators:** Lorraine Canham, MD  
Sharon Savage, MD
- 8:00am **WELCOME & ANNOUNCEMENTS**  
Iris Romero MD, MS
- 8:10am **Celebrating 50 Years of Excellence in Cancer Research: University of Chicago Cancer Center and the CCGOP**  
Kathleen Blazer, EdD, MS, CGC  
Olufunmilayo Olopade, MD
- 8:30 am **The Complex Needs of Families at a High Genetic Risk of Cancer – Learning from Telomere Biology Disorders**  
Sharon Savage, MD
- 8:55 am **KEYNOTE ADDRESS I: Li-Fraumeni Syndrome as a Case Study of the Effect of Early Diagnosis on Outcomes**  
Judy Garber, MD, MPH
- 9:20 am **Genomic Testing in Childhood: Lessons Learned About Family Dynamics**  
Melody Perpich, MS, CGC
- 9:35 am **Q&A**
- 9:55 am **BREAK/EXHIBITS**

### SESSION 2: Gastro-intestinal Diseases

**INTERNATIONAL BALLROOM**

- Moderators:** Sonia Kupfer, MD  
Jeremy Segal, MD, PhD
- 10:30 am **KEYNOTE ADDRESS II: Toward Precision Prevention: Vaccines in Lynch Syndrome**  
Matthias Kloor, MD
- 11:00 am **New Mechanisms of Carcinogenesis in Lynch Syndrome & Clinical Implications**  
Aysal Ahadvoa, PhD
- 11:20 am **The Rising Tide of Colorectal Cancer in Younger Adults: Why Is This Happening & What Do We Do About It?**  
Cathy Eng, MD
- 11:40 am **Shifting Paradigms in CDH1 Management**  
Ophir Gilad, MD
- 12:00 pm **Breakthroughs in Molecular Diagnosis**  
Colin Pritchard, MD, PhD
- 12:20 pm **Q&A**
- 12:40 pm **GENERAL LUNCHEON SEATING**  
**STATE ROOM**

12:50 pm **OPTIONAL NON CME PRODUCT THEATER**  
**GOLD ROOM**  
Presented by Cancer IQ  
Expert Roundtable on the Value of Genetic Testing for Cancer Risk Assessment

### SESSION 3: Concurrent Case Presentations with Interprofessional Panel Discussions

- 1:45 pm **1. Molecular Tumor Boards – How Are Suspected Germline Variants Typically Handled at Your Institution's Molecular Tumor Board: Is There a Set-up Process for Germline Referral/Testing?**  
**ROUGE ROOM (1<sup>ST</sup> FLOOR)**
- Moderators:** Cara Essling, MMSPA  
Bita Nehoray, MS, CGC
- Faculty Panel:** Kara Maxwell, MD, PhD  
Colin Pritchard, MD  
Padma Sheila Rajagopal, MD, MPH, MSc, NCI  
Ari Rosenberg, MD  
Jeremy Segal, MD, PhD  
Rajat Thawani, MBBS
- 2. Breast, Ovarian, GI, Endometrial Cancers High and Moderate Risk, & Risk Management**  
**INTERNATIONAL BALLROOM**
- Moderators:** Christine Drogan, MS, CGC  
Emma Keel, MS, CGC
- Faculty Panel:** Cathy Eng, MD  
Judy Garber, MD, MPH  
Matthias Kloor, MD  
Sonia Kupfer, MD  
Jeffrey Weitzel, MD

### 3. Hematologic, Pediatric and New Syndromes

**CUVEE (1ST FLOOR)**

- Moderators:** Rachelle Manookian, MS, CGC  
Melody Perpich, MS, CGC
- Faculty Panel:** Lorraine Canham, MD  
Jane Churpek, MD, MS  
Michael Drazer, MD, PhD  
William Foulkes, MBBS, PhD  
Sharon Savage, MD

2:45 pm **BREAK/EXHIBITS**

### SESSION 4: New Approaches to Early Diagnosis and Treatment of Inherited Cancers

**INTERNATIONAL BALLROOM**

- Moderators:** Jane Churpek, MD, MS  
Padma Sheila Rajagopal, MD, MPH, MSc, NCI
- 3:00 pm **KEYNOTE ADDRESS III: The Promise of Multi-Cancer Detection Assays**  
Peter Kuhn, MD
- 3:30 pm **MicroRNA Biogenesis Proteins, Ontogenesis to Oncogenesis**  
William Foulkes, MBBS, PhD

CONTINUED...

# AGENDA

PROGRAM AGENDA AND SPEAKER SELECTION SUBJECT TO CHANGE.

3:50 pm **Predicting Response and Toxicities to Immunotherapy**  
Peter O'Donnell, MD

4:30 pm **Q&A**

4:50 pm **ADJOURN**

5:00 pm **POSTER RECEPTION**  
**GOLD ROOM**

Food and beverage to be served

*See back pages for poster numbers and presenters*

## SATURDAY, APRIL 20, 2024

7:30 am **REGISTRATION, BREAKFAST AND EXHIBITS**  
**INT'L. BALLROOM FOYER**

8:10am **ANNOUNCEMENTS**  
Kathleen Blazer, EdD, MS, CGC  
Olufunmilayo Olopade, MD

**SESSION 5: Research Highlights**  
**INTERNATIONAL BALLROOM**

**Moderator:** Sonia Kupfer, MD  
Dengzeng Huo, PhD

8:15 am **Advanced Personalized Risk Assessment: Making Meaning out of PRS and Model Output**  
Lisa Madlensky, PhD, CGC

8:35 am **Update from International Consortia Studies**  
Katherine Nathanson, MD

8:55 am **KEYNOTE ADDRESS IV: Update from All of Us Study**  
Karriem Watson, DHSc, MS, MPH

9:25 am **No One Left Behind: Enhancing Equity in Genomic Testing and Screening - Highlights from the WISDOM Study**  
Yiwey Shieh, MD

9:45 am **Q&A**

10:00 am **BREAK/EXHIBITS**

**SESSION 6: Updates from the Global Community of Practice**  
**INTERNATIONAL BALLROOM**

10:30 am **RESEARCH PRESENTATIONS**

**Moderators:** Raja Pramanik, MBBS, MD, DM, BA  
Jeffrey Weitzel, MD

**Faculty Panel:** Oral Abstract Presenters

*Please reference the oral abstract presentations page for more info*

11:30 am **Patient Centered Genetic Counseling - What are We Learning from Our Patients?**

**Moderators:** Grace-Ann Fasaye, ScM, CGC  
Feighanne Hathaway, MS, CGC

**Faculty Panel:** Michelle Bruszer  
Wenora Johnson  
Helen Palmquist  
Parul Somani

12:30 pm **GENERAL LUNCH SEATING**  
**STATE ROOM**

12:50 pm **OPTIONAL NON CME**  
**PRODUCT THEATER**  
**GOLD ROOM**

Presented by Astra Zeneca  
Precision Medicine

**Detecting PIK3CA, AKT1, and PTEN alterations using NGS**

**Speaker:** Justin Grahl, PharmD  
Precision Medicine and Clinical Oncology Pharmacist at Froedtert Cancer Center and the Medical College of Wisconsin

**SESSION 7: Using Genetics for Precision Prevention**  
**INTERNATIONAL BALLROOM**

**Moderators:** Iris Romero, MD, MS  
Lucy Godley, MD, PhD

1:30 pm **Introduction to Harvey Golomb Distinguished Lecture Series**  
Olufunmilayo Olopade, MD

2:00 pm **Distinguished Lecturer Lessons Learned over 30 years as a Clinical Cancer Geneticist**  
Stephen Gruber, MD, PhD, MPH

2:30 pm **Q&A**

2:45 pm **BREAK/EXHIBITS**

**SESSION 8: Town Hall Case Discussions with Interprofessional Panel**

3:00 pm **1. Solid Tumor Breakout**  
**INTERNATIONAL BALLROOM**

**Moderator:** Olufunmilayo Olopade, MD  
Rodrigo Santa Cruz Guindalini, MD, PhD

**Faculty Panel:** Stacy Gray, MD  
Nora Jaskowiak, MD  
Kara Maxwell, MD, PhD  
Jeremy Segal, MD, PhD  
David Vanderweele, MD, PhD

**2. Hematologic Malignancies**  
**GOLD ROOM**

**Moderators:** Michael Drazer, MD, PhD  
Feighanne Hathaway, MS, CGC

**Faculty Panel:** Daniel Arber, MD  
Jane Churpek, MD, MS  
Afaf Osman, MD  
Caner Saygin, MD  
Wendy Stock, MD

5:00 pm **ADJOURN**

6:30- **EVENING GALA**

9:30pm **ROUGE ROOM (1<sup>ST</sup> FLOOR)**  
Sponsored by Astra Zeneca  
Precision Medicine

## SUNDAY, APRIL 21, 2024

7:30 am **REGISTRATION, BREAKFAST AND EXHIBITS**  
**INT'L. BALLROOM FOYER**

8:10am **ANNOUNCEMENTS**  
Kathleen Blazer, EdD, MS, CGC  
Olufunmilayo Olopade, MD

**SESSION 9: At the Frontier of Breast Cancer Research**  
**INTERNATIONAL BALLROOM**

**Moderators:** Frederick Howard, MD  
Loren Saulsberry, PhD

8:15 am **AI for Breast Screening**  
Adam Yala, PhD

8:35 am **Targeting DNA Repair Pathways and Immune Modulation in TNBC**  
Rita Nanda, MD

9:00 am **KEYNOTE ADDRESS V: Developing Vaccines for Cancer Interception**  
Susan Domchek, MD

9:30 am **MRI Surveillance and Mortality in BRCA1 and BRCA2 Mutation Carriers**  
Steven Narod, MD

10:00 am **Breast Cancer in Young Women - Results from Breast Cancer Family Registry**  
Mary Beth Terry, PhD

10:30 am **Q&A**

10:45 am **BREAK/EXHIBITS**

**SESSION 10: At the Frontier of Ovarian Cancer Research**  
**INTERNATIONAL BALLROOM**

**Moderators:** Pamela Ganschow, MD  
Kathryn Mills, MD

11:00 am **Clinical Classification of Inherited BRCA2 Variants**  
Fergus Couch, PhD

11:30 am **KEYNOTE ADDRESS VI: Impact of Bilateral Salpingo-Ooporectomy on Cancer Incidence and Mortality in Women with a BRCA1 or BRCA2 Pathogenic Variant**  
Kelly Metcalfe, RN, PhD

12:00 pm **Curing Ovarian Cancer: Are We There Yet From a Surgical Perspective?**  
John Moroney, MD

12:30 pm **Is Advanced Ovarian Cancer Curable; Update on Integration of PARP Inhibitors?**  
Gini Fleming, MD

1:00 pm **Q&A**

1:15 pm **CONCLUDING REMARKS**  
Kathleen Blazer, EdD, MS, CGC  
Tuya Pal, MD  
Olufunmilayo Olopade, MD

1:30 pm **ADJOURN**



# ORAL ABSTRACT PRESENTATIONS

## SESSION 6: RESEARCH PRESENTATIONS

Kenn Chi Ndi, MD

**Setting Up Cancer Genetics Counseling and Testing Services in Cameroon**

Carolyn Solomi, V MBBS, DGO, DNB, MRCOG

**Genetic Threads of Hope: Unraveling Germline Mutations in Ovarian Cancer, their Impact on Clinical Outcomes and Empowering Ovarian Cancer Defense with Cascade Genetic Testing — an Indian Perspective**

Marina Candido Visontai Cormedi, MD

**Developing a Polygenic Risk Score for Precision Prevention of HR+/HER2- Breast Cancer in Brazilian Women**

Linda Ann Smith, MD

**Following Circulating Tumor DNA in Breast Cancer Patients to Enhance Treatment Options**

Daniel G. Luba, MD


**Hereditary Cancer Screening in a GI Practice in Monterey County, California**

Lauren Banaszak, MD

**Implementation and Practicality of Guideline-Driven Germline Genetic Evaluation Criteria in the Care of Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia**

Ta-Chueh Melody Rosenberg, MSN, AGACNP-BC, OCN

**Reducing A Specific Barrier to Cancer Genetic Testing for Veterans: Service Connection Discrimination Concern**



# POSTERS



## POSTER 1

Morgan Devlin, MS, LCGC  
Ascension St. John  
**Patient Insurance Literacy and Awareness of Financial Resources: A Quality Improvement Project in a Detroit Community Cancer Genetics Clinic**

## POSTER 2

Lauren Banaszak, MD  
University of Wisconsin-Madison  
**Implementation and Practicality of Guideline-Driven Germline Genetic Evaluation Criteria in the Care of Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia**

## POSTER 3

Vera Cherepakho, MS, LGC  
Kaiser Permanente Division of Research  
**Validation of Patient Facing Online Risk Assessment Tool for Population Screening of Hereditary Cancer**

## POSTER 4

Sarah (Nielsen) Young, MS, CGC  
Invitae Corp.  
**Real-World Breast Surgery Utilization among Breast Cancer Patients with Germline Variants of Uncertain Significance**

## POSTER 5

Lee Ann Daly, MS, CGC  
NYU Langone Health  
**Biallelic BRCA2 Mutations and Negative Chromosome Breakage Analysis in a Patient With Adult Onset Breast and Colon Cancers**

## POSTER 6

Ashley Lynn Hendershot, DNP, FNP-C, ACGN  
University of Rochester Medical Center  
**Evaluation of a Collaborative Institutional Relationship to Increase Regional Hereditary Cancer Genetic Testing in Individuals with Cancer**

## POSTER 7

Guillermo Alberto, MD  
Instituto Alexander Fleming  
**Co-Occurrence of Germline Pathogenic Variants In BRCA1 or BRCA2 and Lynch Syndrome Genes: First Report in South American Population of Three Unrelated Argentinian Families**

## POSTER 8

Ophir Gilad, MD  
University of Chicago  
**Birth Cohort Effect on Age of Colorectal Cancer Onset in Lynch Syndrome**

## POSTER 9

Kenn Chi Ndi, MD  
Yaounde General Hospital  
The University of Yaounde 1, Cameroon  
**Setting Up Cancer Genetics Counseling and Testing Services in Cameroon**

## POSTER 10

Heather Hannon, DNP APRN-NP ACGN  
Bon Secours Cancer Institute  
**Promoting Adherence to Germline Genetic Testing for Pancreatic Adenocarcinoma**

## POSTER 11

Britt Johnson, PhD, FACMG  
Invitae, Corp  
**Tracking Uncertainty in Germline Genetic Testing for Hereditary Cancer Syndromes: Sources, Attributes, and Resolution of Variants of Uncertain Significance in Over 1 Million Individuals**

## POSTER 12

Ed Esplin, MD, PhD, FACMG, CGAF, FACP  
Invitae  
**One of These is Not Like The Others: A Descriptive Study of the Attenuated Phenotype of PMS2**

## POSTER 13

Jennifer Diaz, AOCNP, CGRA, APRN  
Medical University of South Carolina  
**Experience with a Pathogenic Variant Clinic**

## POSTER 14

Kristie Bobolis, MD  
Sutter Medical Group  
**Pure Lobular Carcinoma In Situ Presenting as a Palpable Mass in an Individual with a Germline Pathogenic Variant in CDH1**

## POSTER 15

Thomas (T.J.) Slavin, MD  
HALO Research Institute  
**Cancer Risks Associated with Germline Pathogenic Variants in MLH1, MSH2, MSH6, PMS2, and EPCAM genes**

## POSTER 16

Jennifer Thalita Targino dos Santos, MS  
University of São Paulo  
**Using Design Thinking to Improve the Identification of Patients At Risk For Hereditary Neoplastic Syndromes**

## POSTER 17

Alexandra Capasso, MS, CGC  
City of Hope  
**Genetic Counselors' Facilitation of Informed Consent and the Utility of Supplemental Education Tools for Alternate Approaches to Pre-test Counseling for Hereditary Cancer Predisposition**

## POSTER 18

Carolin Solomi. V, MBBS, DGO, MS, DNB, MRCOG  
All India Institute of Medical Sciences,  
New Delhi, India  
**Genetic Threads of Hope: Unraveling Germline Mutations in Ovarian Cancer, Their Impact On Clinical Outcomes and Empowering Ovarian Cancer Defense With Cascade Genetic Testing — An Indian Perspective**

CONTINUED...

# POSTERS

## POSTER 19

Daniel G Luba, MD  
Monterey Bay GI Consultants  
**Hereditary Cancer Screening in a GI Practice In Monterey County, California**

## POSTER 20

Owen Mitchell, B.S.  
University of Chicago  
**Germline Genetic Testing Hesitancy in Patients With Mesothelioma**

## POSTER 21

Achille Van Christ Manirakiza, MD  
University of Chicago  
**Germline Sequence Variation in Rwandan Breast and Prostate Cancer Cases**

## POSTER 22

Stephane Maria Diaz Montes, MD  
Instituto Nacional de Enfermedades Neoplásicas — Li-Fraumeni Syndrome:  
**A Case Report**

## POSTER 23

Anali Pamela Mora Alferez, MD  
Instituto Nacional de Enfermedades Neoplásicas  
**Constitutional Mismatch Repair Deficiency (CMMRD) With An Incidental Finding in ATM Gene in a Patient With a Malignant Brain Tumor**

## POSTER 24

Cathryn Koptiuch, MS, CGC  
Department of Veterans Affairs  
**Implementation of a National Cancer Genetics Service for the Veterans Health Administration**

## POSTER 25

Tessa Bachinski, MS, CGC  
Advocate Health  
**Cancer Diagnoses in Individuals Identified to Have a CHEK2 Pathogenic or Likely Pathogenic Variant: A Multi-Center, Multi-State Retrospective Cohort Study**

## POSTER 26

Rachel Epstein, MS, CGC  
Endeavor Health (formerly NorthShore University HealthSystem)  
**The Breast Health Assessment: A family Health History Screening Tool Using the Electronic Health Record to Facilitate Hereditary Cancer Genetic Testing At the Time of Screening Mammogram**

## POSTER 27

Lindsay Fosler, MS, CGC  
Invitae  
**The Estimated Healthcare Spend to Identify 1 Hereditary Cancer Syndrome Patient with a Deep Intronic Pathogenic Variant By RNA Sequencing is Nearly 500x More Costly Than Identifying 1 Patient With Multi-Gene Panel DNA Testing**

## POSTER 28

Lindsay Fosler, MS, CGC  
Invitae  
**Utility of RNA Analysis in Genetic Testing for Hereditary Cancer is Highly Similar Between Large Cohorts From Two Independent Laboratories**

## POSTER 29

Marina Candido Visontai Cormedi, MD  
University of Sao Paulo  
**Developing A Polygenic Risk Score For Precision Prevention of HR+/HER2- Breast Cancer in Brazilian Women**

## POSTER 30

Michelle Weaver Knowles, FNP, CBCN,  
ONCCG, ACGN, CGRA  
Ava Health  
**Ava Health the Voice for Others**

## POSTER 31

Angelina Izguerra, Research Associate, BPH  
University of Illinois Cancer Center  
**Universal Hereditary Cancer Risk Assessment (uHCRA) with Navigation in an FQHC Primary Care Setting**

## POSTER 32

Heather Hannon, DNP APRN-NP ACGN  
Bon Secours Cancer Institute  
**Beyond the Obvious Involving the Genetic Expert is Key to Ensuring Comprehensive, Guideline-Based Care**

## POSTER 33

Linda Ann Smith, MD  
X-Ray Associates of New Mexico  
**Following Circulating Tumor DNA in Breast Cancer Patients to Enhance Treatment Options**

## POSTER 34

Najeb Ullah Khan, PhD  
Institute of Biotechnology and Genetic Engineering  
**Genetic Susceptibility and Epidemiological Trends of Breast Cancer in the Pashtun Population of Khyber Pakhtunkhwa, Pakistan: Implications for Precision Medicine**

## POSTER 35

Brenda R. Grimes, PhD  
Eli Lilly and Company  
**Genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2-, node-positive, high-risk early breast cancer in the monarchE trial**

## POSTER 36

Susan Shehayeb, MS, CGC  
City of Hope  
**Prevalence and Penetrance of LZTR1 Pathogenic Variants: To Screen or Not to Screen?**

## POSTER 37

Elyssa Zukin, MS, CGC  
City of Hope  
**Uptake of a Chatbot for Disclosure of Germline Genetic Test Results through a Universal Genetic Testing Program**

## POSTER 38

Bitu Nehoray, MS, CGC  
City of Hope  
**Feasibility of Whole Body MRI and Multicancer Early Detection Testing in People at High Risk for Cancer Development**

## POSTER 39

Bitu Nehoray, MS, CGC  
City of Hope  
**Variants at Variance: An Assessment of Discordant Classifications and Phenotypes among TP53 Variants from the International LIFT UP Study**

## POSTER 40

Rachelle Manookian, MS, CGC  
City of Hope  
**Have We Considered Mosaicism? A Nearly Missed Molecular Diagnosis of von Hippel-Lindau**

## POSTER 41

Elise Sobotka, MS, MPH, CGC  
City of Hope  
**Prevalence of CDKN2A Pathogenic Variants in a Large Institutional Cohort: Scrutinizing the Common p.Ile49Thr Variant**

## POSTER 42

Anuja Chitre, MS, CGC  
City of Hope  
**Prevalence and Penetrance of SPINK1 Pathogenic Variants: A Burden to Patients and Providers**

## POSTER 43

Anuja Chitre, MS, CGC  
City of Hope  
**Healthcare Utilization Among Individuals Diagnosed with Lynch Syndrome Through a Universal Germline Genetic Testing Program**

## POSTER 44

Aleck Cervantes  
City of Hope  
**Bridging Data For LIFT UP: Successes and Challenges in International Pedigree Data Collaboration**

## POSTER 45

Rossella Graffeo MD  
Oncology Institute of Southern Switzerland  
**Breast Cancer Patients with Pathogenic Variants in High Penetrance Genes: Risk Reducing Contralateral Mastectomy Decision in a Breast Centre of Southern Switzerland**

# DISCLOSURES

## DISCLOSURE DECLARATIONS

As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.

Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.

### The following individuals have no relevant financial relationships with ineligible companies to disclose:

Aysel Ahadova, PhD	Bitu M. Nehoray, MS
Daniel A. Arber, MD	Olufunmilayo I. Olopade, MBBS, FASCO
Lauren G. Banaszak, MD	Tuya Pal, MD
Lorraine E. Canham, MD	Helen S. Palmquist, BA
Kenn Chi Ndi, MD	Melody Perpich, MS, CGC
Jane E. Churpek, MD, MS	Raja Pramanik, MD, DM
Michael William Drazer, MD, PhD	Colin C. Pritchard, MD, PhD
Sandra Dreike, MS, CGC	Padma S. Rajagopal, MD, MPH, MSc
Christine Drogan, MS	Iris Romero, MD
Cara Essling, MMS, PA-C	Ta-Chue Rosenberg, MSN
Grace Ann Fasaye, ScM, CGC	Katherine G. Roth, MD
William D. Foulkes, MBBS, PhD	Loren Saulsberry, PhD
Pamela Sue Ganschow, MD	Sharon A. Savage, MD
Judy E. Garber, MD, MPH	Caner Saygin, MD
Ophir Gilad, MD	Susan S. Shehayeb, MS, CGC
Lucy Godley, MD, PhD	Yiwey Shieh, MD
Stacy Wang Gray, MD, AM	Linda Smith, MD
Stephen Gruber, MD, PhD, MPH	Elise P. Sobotka, MS, MPH, CGC
Denzeng Huo, MD, PhD	Carolyn Solomi, MBBS, DGO, MS, MRCOG
Nora T. Jaskowiak, MD	Elana Solomon, ScM, MA
Emma M. Keel, MS, CGC	Mary Beth Terry, PhD
Sonia Kupfer, MD	Rajat Thawani, MD
Daniel G. Luba, MD	Karriem S. Watson, DHSc, MS, MPH
Lisa Madlensky, PhD, CGC	Elyssa C. Zukin, MS, CGC
Rachelle Manookian, MS, CGC	
Kara N. Maxwell, MD, PhD	
John W. Moroney, MD	
Steven Narod, MD	

## DISCLOSURE STATEMENTS

**Kathleen R. Blazer, EDD, MS** receives research support from Pfizer and AstraZeneca.

**Michelle Bruszer** is employed by Sonova Hearing Aid Manufacturer.

**Marina Candido Visontai Cormedi, MD** serves as a sub-investigator for AstraZeneca, as a speaker for Fleury Genomica, and receives institutional research funding from Novartis.

**Fergus J. Couch, PhD** receives research support from Grail.

**Susan M. Domchek, MD** served as a consultant for AstraZeneca and GSK.

**Cathy Eng, MD** serves as a consultant for Amgen, Elevation, GSK, GE, IGM, Merck, Natera, Pfizer, Seagen, Taiho and receives institutional research funding from Janssen, Merck, Gritstone, and Hutchinson.

**Gini F. Fleming, MD** has received institutional research funding from Roche, Iovance, Sermonix, Computer, Celldex, Correct, AstraZeneca, Molecular Templates, Astellas, K Group Beta, and Pfizer. Dr. Fleming plans to discuss investigational/unapproved use of withdrawn PARPI indications and ongoing studies, as well as trials attempting to overcome PARPI resistance, ATR inhibitors, and weel inhibitors.

**Feighanne Hathaway, MS, CGC** serves as a consultant for AstraZeneca.

**Frederick M. Howard, MD** serves as a consultant for Novartis AG.

**Joanne M. Jeter, MD, MS** served as a private investigator for research study for BioAtla. Dr. Jeter plans to discuss investigational/unapproved use of vaccination for Lynch syndrome, PARP inhibitors for non-BRCA mutations in HRD tumors, and tumor type-independent matching of mutations and targeted therapies.

**Wenora Johnson** serves as a speaker for GSK.

**Matthias Kloor, MD** serves as a speaker for Roche.

**Peter Kuhn, PhD** serves as an advisor to Quest Diagnostics and as a consultant to Epic Sciences and Cansera.

**Kelly Metcalfe, RN, PhD** serves as a consultant for AstraZeneca.

**Kathryn Mills, MD** serves as a speaker and consultant for Stryker.

**Rita Nanda, MD** serves on the advisory board for AstraZeneca, Beyond Spring Pharma, Daiichi Sankyo, Fujii Film/GE, Gilead, Infinity Pharmaceuticals, iTeos Therapeutics, MacroGenics, Merck, Novartis, OBI Pharma, OncoSec, Pfizer, Sanofi, Seagen, and Stemline Therapeutics. Dr. Nanda has received grant funding to her institution from Arvinas, AstraZeneca, Celgene, Corcept Therapeutics, Genentech/Roche, Gilead/Immunomedics, Merck, Novartis, OBI Pharma, OncoSec, Pfizer, Relay Therapeutics, Seattle Genetics, Sun Pharma, and Taiho Oncology.

**Katherine Nathanson, MD** serves on the advisory board for Merck.

**Peter O'Donnell, MD** receives honoraria from Adept Field Solutions, Advarra, Merck, Astellas, AbbVie, Pfizer, Custom Learning Designs, Axiom Healthcare Strategies, EMD Serono, IntrinsicQ, ISMIE, NAMCP, Seagen, Curio Science, FirstWord, MedLearning Group, Research to Practice, Great Debates and Updates, MJH Life Sciences, Peerview, Vaniam Group, Institute for Enquiring Minds, Pharmavision UK, PRIME Education LLC, Amerisource Bergen, Health Advances, Parexel Intl Corp, Vida Ventures LLC, Curio Science, Astellas, Seagen, Janssen, Nektar, Dragonfly Therapeutics, and G1 Therapeutics.

**Dr. O'Donnell** receives institutional research funding from Boehringer Ingelheim, Merck, Genentech/Roche, AstraZeneca/MedImmune, Acerta Pharma, Janssen, Seagen, Bristol Myers Squibb, and Astellas Pharma.

CONTINUED...

